Kirilys Therapeutics also said that it licensed KRLS-017, its lead compound, from Ube Industries. The company said the financing round will enable Kirilys to complete all activities through the Investigational New Drug filing of KRLS-017, as well as preparatory work for the phase I clinical development program.

KRLS-017, a reversible small molecule inhibitor of cyclin dependent kinase 7 (CDK7), showed selectivity and antitumor efficacy along with very favorable properties for an oral drug, Kirily's said.

Finally, the company reported that it also completed a partnership agreement with D2G Oncology, which uses genetically defined animal tumor models to reveal relationships between cancer genotypes and drug efficacy.